Antimicrobial resistance is one of the major challenges facing modern healthcare. As bacteria develop resistance to commonly used antibiotics, treating certain bacterial infections becomes increasingly difficult. One important area of research and clinical interest is the use of aztreonam-avibactam, a combination designed to address specific mechanisms of bacterial resistance.
Understanding how aztreonam-avibactam works, why the two agents are combined, and how the combination interacts with bacterial resistance mechanisms can help healthcare professionals and medical science readers better understand its role in antimicrobial therapy.
What Is Aztreonam-Avibactam?
Aztreonam-avibactam is a combination of two agents: aztreonam, a monobactam antibiotic, and avibactam, a beta-lactamase inhibitor.
Aztreonam acts against susceptible Gram-negative bacteria by interfering with bacterial cell-wall synthesis. Avibactam inhibits certain beta-lactamase enzymes that bacteria produce to break down beta-lactam antibiotics.
The combination is particularly important in the context of certain multidrug-resistant Gram-negative bacteria, including organisms that produce metallo-beta-lactamases (MBLs).
The two agents have complementary roles: aztreonam can remain active against bacteria producing MBLs, while avibactam can inhibit certain other beta-lactamases that might otherwise compromise aztreonam’s activity.
How Does Aztreonam-Avibactam Work?
The mechanism of action of aztreonam-avibactam involves two complementary processes.
1. Aztreonam Inhibits Bacterial Cell-Wall Synthesis
Aztreonam belongs to the monobactam class of antibiotics. It acts by binding to susceptible penicillin-binding proteins, particularly PBP3 in Gram-negative bacteria, and interfering with the processes required to build and maintain the bacterial cell wall.
Disruption of cell-wall synthesis can lead to bacterial cell death in susceptible organisms.
However, bacteria may produce beta-lactamase enzymes that degrade aztreonam, limiting its antibacterial activity.
2. Avibactam Inhibits Certain Beta-Lactamases
Avibactam is a non-beta-lactam beta-lactamase inhibitor. It inhibits several important classes of beta-lactamases, including many class A, class C, and certain class D enzymes.
These enzymes can break down antibiotics and contribute to antimicrobial resistance.
Avibactam does not inhibit metallo-beta-lactamases themselves. Instead, its role in this combination is to inhibit other susceptible beta-lactamases that may otherwise inactivate aztreonam.
3. Why Are Aztreonam and Avibactam Combined?
Metallo-beta-lactamases, including NDM, VIM, and IMP enzymes, can inactivate many beta-lactam antibiotics. Aztreonam is generally stable against hydrolysis by these enzymes, but bacteria may simultaneously produce other beta-lactamases capable of inactivating aztreonam.
By inhibiting certain of these additional enzymes, avibactam can help protect aztreonam’s activity against susceptible bacteria.
This complementary mechanism is the scientific rationale behind the aztreonam-avibactam combination.
Aztreonam-Avibactam and Metallo-Beta-Lactamase-Producing Bacteria
Metallo-beta-lactamases are enzymes that can confer resistance to several important beta-lactam antibiotics, including carbapenems.
Examples include:
- New Delhi metallo-beta-lactamase (NDM)
- Verona integron-encoded metallo-beta-lactamase (VIM)
- Imipenemase metallo-beta-lactamase (IMP)
Bacteria producing these enzymes may also carry genes for other resistance mechanisms. This can make treatment selection more complex.
The aztreonam-avibactam combination has been developed to address a specific weakness in these resistance mechanisms: MBLs may inactivate other antibiotics, but they do not directly hydrolyze aztreonam. Avibactam can inhibit certain co-produced serine beta-lactamases.
The effectiveness of the combination still depends on the bacterial species, additional resistance mechanisms, susceptibility results, and the clinical context.
Potential Clinical Significance
Aztreonam-avibactam has an important role in the development of treatment options for selected infections caused by resistant Gram-negative bacteria.
Its clinical significance is associated with:
- A complementary antibiotic and beta-lactamase inhibitor mechanism.
- Activity against certain bacteria producing metallo-beta-lactamases when the organisms are susceptible.
- The ability to address some resistance mechanisms that may otherwise compromise aztreonam.
- Its relevance to antimicrobial stewardship and the management of difficult-to-treat bacterial infections.
It is important to remember that the combination is not effective against every resistant organism. Treatment decisions must be based on appropriate susceptibility testing, clinical assessment, approved prescribing information, and applicable treatment guidelines.
Aztreonam-Avibactam and Antimicrobial Resistance Research
Research into aztreonam-avibactam illustrates why understanding bacterial resistance mechanisms is essential for antibiotic development.
Resistance is not always caused by a single enzyme. Bacteria may produce multiple beta-lactamases, alter antibiotic targets, reduce membrane permeability, or express efflux mechanisms.
A combination approach can address some of these mechanisms, but it cannot overcome every form of resistance.
Ongoing surveillance, microbiological testing, responsible antibiotic use, and continued research are therefore important for preserving the effectiveness of available antimicrobial treatments.
Understanding Meblanios and Aztreonam-Avibactam
For readers interested in the pharmaceutical product associated with this combination, AIONIOS Pharma provides a dedicated product page for Meblanios — Aztreonam and Avibactam Injection.
The product page provides information about Meblanios and its stated composition. Readers should consult the product’s verified prescribing information and applicable medical guidance for details about approved uses, safety, and administration.
Product information should not be interpreted as a substitute for clinical evaluation or professional prescribing advice.
Frequently Asked Questions
What is aztreonam-avibactam?
Aztreonam-avibactam is a combination of the monobactam antibiotic aztreonam and the beta-lactamase inhibitor avibactam. It is designed to address certain beta-lactam resistance mechanisms in Gram-negative bacteria.
Why is avibactam combined with aztreonam?
Avibactam inhibits certain beta-lactamases that may otherwise break down aztreonam. This can help preserve aztreonam’s activity against susceptible bacteria that produce metallo-beta-lactamases alongside other beta-lactamases.
Does avibactam inhibit metallo-beta-lactamases?
No. Avibactam does not directly inhibit metallo-beta-lactamases. The combination works because aztreonam is generally stable against hydrolysis by MBLs, while avibactam inhibits certain other beta-lactamases that may compromise aztreonam.
Is aztreonam-avibactam effective against all resistant bacteria?
No. Its activity depends on the organism and its resistance mechanisms. Susceptibility testing and clinical assessment are important when determining whether the combination is appropriate.
Where can I find information about Meblanios?
You can visit the Meblanios product page on AIONIOS Pharma for the available product information.
Conclusion
Aztreonam-avibactam represents an important approach to addressing selected beta-lactam resistance mechanisms in Gram-negative bacteria. Aztreonam provides antibacterial activity against susceptible organisms, while avibactam inhibits certain additional beta-lactamases that could otherwise compromise its activity.
Understanding this complementary mechanism helps explain the combination’s relevance to antimicrobial resistance research and the management of selected difficult-to-treat infections. Appropriate use depends on accurate microbiological assessment, clinical judgment, and verified prescribing information.